Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

Inclusion Criteria: * Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol. * A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination. * Written informed consent obtained from the parent(s)/Legally Acceptable Representative(s) of the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. * Infants who have received a previous dose of hepatitis B immunoglobulin after birth. Exclusion Criteria: * Child in care. * Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs with the exception of Hepatitis B immunoglobulin since birth. Child is unlikely to remain in the study area for the duration of the study. * Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Previous vaccination against rotavirus. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Family history of congenital or hereditary immunodeficiency. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * Major congenital defects or serious chronic illness. * Acute disease and/or fever at the time of enrolment. * Administration of immunoglobulins (with the exception of HBIG) and/or any blood products since birth or planned administration during the study period. * Gastroenteritis within 7 days preceding the study vaccine administration. * Previous confirmed occurrence of Rotavirus gastroenteritis.